Blocking PD-L2 prevents senescent cell accumulation and age-related dysfunction

Selim Chaib and colleagues studied programmed death ligand 2, or PD-L2, as an immune checkpoint on senescent cells. PD-L2 was upregulated in isolated senescent human cells and during aging. Senolytic treatment removed age-associated cells with high PD-L2 expression. Aged PD-L2 knockout mice accumulated fewer senescent cells than wild-type mice and had better insulin sensitivity and grip strength. Anti-PD-L2 therapy restored insulin sensitivity in aged wild-type mice. The proposed mechanism is immune evasion: PD-L2 may help senescent cells persist by limiting immune clearance. The study identifies a possible target for senescence biology and may explain why some senolytic strategies work selectively. It does not establish a human treatment. Immune checkpoints are clinically important. Blocking them can produce inflammatory and autoimmune adverse events, and the paper does not provide a human dose, delivery route, or long-term safety profile. Several authors hold patents related to PD-L2 and senolytic uses, and one author reports financial interests in companies active in senescence research. The result is a preclinical mechanism, not evidence to use checkpoint drugs for aging or to self-experiment with cancer immunotherapies.

Targeting PD-L2 in senescent cells may be a strategy for alleviating the age-related dysfunction associated with cellular senescence.